1. Netherlands Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
VALUE8 NV

VALUE8 NV

6.50
EUR
+0.15
(+2.36%)
62.43MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.34
15.24
17.43
0.29
0.16
1.29
0.61
0.08
0.43
0.43
0.34
0.56
0.3
- -
Basic EPS, GAAP
0.57
0.71
0.68
-0.2
2.3
0.42
0.44
0.9
1.89
-0.26
0.61
0.74
1.76
- -
Free Cash Flow per Basic Share
0.68
-0.27
-0.07
-0.95
0.5
3.34
1.28
-1.55
-1.27
0.43
-0.13
0.66
-1.21
- -
Dividend per Share
0.07
0.11
0.13
0.19
- -
1.11
0.15
0.15
0.07
0.17
0.05
0.14
0.08
- -
Book Value per Share
5.19
6.16
6.83
7.47
8.62
6.76
6.67
8.03
9.84
9.53
10.07
10.66
12.33
12.33
Tangible Book Value per Share
0.82
3.21
1.27
7.47
8.61
6.75
6.67
8.03
9.84
9.53
10.07
10.66
12.33
12.33
Basic Weighted Avg Shares
5
6
8
8
9
10
10
10
10
10
10
10
10
10
Sales/Revenue/Turnover
103
98
134
2
1
13
6
1
4
4
3
5
3
- -
Operating Margin (%)
-1.97
0.32
-0.91
41.14
1,527.49
34.97
77.38
1,167.2
454.37
-64.94
192.02
137.14
628.79
- -
Depreciation Expense
2
2
5
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
3
5
5
-2
21
4
5
9
18
-3
6
7
17
- -
Effective Tax Rate (%)
12.76
9.58
4.73
- -
- -
- -
0.75
- -
- -
- -
- -
- -
2.36
- -
Profit Margin (%)
2.97
4.65
3.89
-70.25
1,480.43
32.52
72.51
1,171.49
442.56
-60.94
177.17
132.57
588.18
- -
Working Capital
12
22
16
-4
-7
17
35
36
37
26
23
29
-7
-7
LT Debt
11
9
17
20
- -
3
3
- -
2
- -
- -
- -
- -
- -
Total Equity
37
50
62
76
79
72
71
78
96
92
97
103
119
119
Return on Invested Capital (%)
-4.63
0.49
7.13
- -
- -
- -
6.37
- -
19.72
- -
6.25
7.09
14.36
- -
Return on Capital (%)
6.77
7.36
9.27
- -
- -
- -
6.09
- -
19.71
- -
6.19
7
14.21
- -
Return on Common Equity (%)
12.56
12.43
10.41
-2.67
28.66
5.7
6.27
11.71
21.2
-2.7
6.19
7.17
15.28
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
5
6
18
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
1
1
1
Shares Outstanding
10
10
10
Market Capitalization
56
60
62

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
36
8
13
Cash, Cash Equivalents & STI
35
8
12
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
8
20
Payables & Accruals
- -
- -
- -
ST Debt
5
6
18
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.3%
9.13%
15.68%
Free Cash Flow
31.81%
-232.23%
-283.17%
Net Income, GAAP
-165.47%
-34.8%
136.48%
Sales/Revenue/Turnover
100.54%
90.69%
-46.7%
Total Cash Common Dividend
- -
26.29%
-46.64%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3
2024
- -
- -
5
2025
- -
- -
3

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.61
2024
- -
- -
0.74
2025
- -
- -
1.76

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.05
2024
- -
- -
0.14
2025
- -
- -
0.08

Company Description

Company Profile APIChatGPT
CEO
Peter-Paul Ferdinand de Vries
Full Time Employees
2,009
Sector
Health services
Industry
Medical/Nursing services
Address
Brediusweg 33 Bussum NH Netherlands 1401 AB
IPO Date
Sep 24, 2008
Website
value8.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Value8 N.V. (VALUE.AS) is a Netherlands-based investment holding company that engages in long-term investments in undervalued small- and mid-cap companies across various sectors, including healthcare, technology, manufacturing, and sustainable energy; it provides active shareholder involvement, strategic advisory services, and portfolio management to enhance value creation for its investee companies. The company offers services such as equity investments, board representation, operational improvements, and exit strategies through IPOs or trade sales; its investment portfolio includes stakes in companies like Beter Bed N.V., Heiploeg Group, and SnowWorld N.V., with a focus on European markets. Founded in 2010 and headquartered in Alkmaar, Netherlands, Value8 operates primarily in Europe, targeting institutional and private investors seeking growth-oriented opportunities in niche markets. In recent developments, Value8 announced a strategic partnership with a leading Dutch pension fund in early 2025 to co-invest in sustainable technology firms, expanding its portfolio into green energy solutions; the company completed the acquisition of a minority stake in a biotech firm specializing in personalized medicine in Q3 2025, marking its entry into advanced healthcare innovations. Additionally, Value8 launched a new €50 million investment fund focused on AI-driven manufacturing in late 2024, which saw oversubscription and subsequent deployments in two portfolio companies; these moves reflect a broader strategic shift toward high-growth tech and sustainability segments amid European market recoveries.